Anticholinergic bronchodilators, such as ipratropium, produce what primary effect in COPD?

Anticholinergic bronchodilators, such as ipratropium, produce what primary effect in COPD?

• A. Increase heart rate markedly
• B. Bronchodilation with drying of secretions
• C. Increase mucus production
• D. Worsen exercise tolerance

Answer: (B)

Anticholinergic bronchodilators relieve COPD by blocking parasympathetic (vagal) input to the airways, which relaxes airway smooth muscle and opens the bronchi. This muscarinic blockade, especially at the M3 receptors, reduces bronchoconstriction, giving bronchodilation as the primary effect. In addition, it dampens glandular secretions in the airways, leading to drying of secretions. So ipratropium mainly provides bronchodilation with drier airway secretions, a combination that helps improve airflow and reduce mucus-related symptoms. Dry mouth is a common, expected side effect due to the same anticholinergic action.

Anticholinergic bronchodilators relieve COPD by blocking parasympathetic (vagal) input to the airways, which relaxes airway smooth muscle and opens the bronchi. This muscarinic blockade, especially at the M3 receptors, reduces bronchoconstriction, giving bronchodilation as the primary effect. In addition, it dampens glandular secretions in the airways, leading to drying of secretions. So ipratropium mainly provides bronchodilation with drier airway secretions, a combination that helps improve airflow and reduce mucus-related symptoms. Dry mouth is a common, expected side effect due to the same anticholinergic action.